Pulmonary hypertension associated with ponatinib therapy

European Respiratory Journal

Volumn 47, Issue 2, 2016, Pages 676-679

  Quilot, Fleur Marie ^a,b   Georges, Marjolaine ^a,b   Favrolt, Nicolas ^a   Beltramo, Guillaume ^a,b   Foignot, Clément ^a,b   Grandvuillemin, Aurélie ^a   Montani, David ^c,d,e   Bonniaud, Philippe ^a,b,f   Camus, Philippe ^a,b,f  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

^e CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^f Institut Médical de Génétique et d Immunologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; DASATINIB; FLUINDIONE; FUROSEMIDE; HYDROXYUREA; IMATINIB; NILOTINIB; PONATINIB; SILDENAFIL; TREPROSTINIL; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ADULT; ADVERSE OUTCOME; ARTERY THROMBOSIS; CASE REPORT; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPNEA; EXUDATE; FEMALE; HEART INDEX; HEART RIGHT VENTRICLE FAILURE; HUMAN; LEG THROMBOSIS; LETTER; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; LUNG WEDGE PRESSURE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; VEIN THROMBOSIS; CHEMICALLY INDUCED; DISEASE COURSE; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; CARDIAC OUTPUT; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; PYRIDAZINES; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84958064169     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01110-2015     Document Type: Letter

References (15)

1. Camus P. Pneumotox II (V2.0, 2012). The Drug-Induced Respiratory Disease Website. www.pneumotox.com Date last accessed: December 17, 2015. Date last updated: December 1, 2015.
2. Montani D, Seferian A, Savale L, et al. Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 2013; 22: 244-250.
3. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 2015; 90: 1060-1064.
4. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
5. Breccia M, Alimena G. Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors. Leuk Res 2013; 37: 713-720.
6. Cortes J, Mauro M, Steegmann JL, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System. Am J Hematol 2015; 90: E66-E72.
7. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013; 369: 1783-1796.
8. FDA Drug Safety Communication: FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales. 2013. www.fda.gov/Drugs/DrugSafety/ucm373040.htm Date last accessed: October 21, 2015. Date last updated: September 1, 2015.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
10. Breccia M, Alimena G. Second-generation tyrosine kinase inhibitors (TKI) as salvage therapy for resistant or intolerant patients to prior TKIs. Mediterr J Hematol Infect Dis 2014; 6: e2014003.
11. Groeneveldt JA, Gans SJ, Bogaard HJ, et al. Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. Eur Respir J 2013; 42: 869-870.
12. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127: 1128-1138.
13. Guignabert C, Tu L, Girerd B, et al. New molecular targets of pulmonary vascular remodeling in pulmonary arterial hypertension: importance of endothelial communication. Chest 2015; 147: 529-537.
14. + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-1406.
15. Nagaraj C, Tang B, Bálint Z, et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85-95.